Preventing clinical deterioration in the course of schizophrenia: The potential for neuroprotection

CNS Spectrums

Volumn 11, Issue 4, 2006, Pages 1-13

  Malaspina, Dolores ^a   Jarskog, L Fredrik ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DISUFENTON SODIUM; HALOPERIDOL; MINOCYCLINE; NEUROLEPTIC AGENT; OLANZAPINE;

BRAIN SIZE; CENTRAL NERVOUS SYSTEM FUNCTION; DISABILITY; DISEASE COURSE; ENVIRONMENTAL FACTOR; EPIGENETICS; HEREDITY; HUMAN; NERVE DEGENERATION; NEUROBIOLOGY; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; STRESS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATROPHY; BRAIN; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PREGNANCY; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33646177718     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223.
2. Kraepelin E. Dementia Praecox. Barclay E, Barclay S, trans. New York, NY: Churchill Livingstone Inc; 1919/1971.
3. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50(11):884-897.
4. Erratum in: Biol Psychiatry. 2002;51(4):346.
5. Kraepelin E. Dementia Praecox. Barclay E, Barclay S, trans. New York, NY: Churchill Livingstone Inc: 1919/1971.
6. Gottesman II, Shields J. Schizophrenia: The Epigenetic Puzzle. Cambridge, UK: Cambridge University Press; 1982.
7. Krabbendam L, van Os J. Schizophrenia and urbanicity: a major environmental influence-conditional on genetic risk. Schizophr Bull. 2005;31(4):795-799.
8. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31(3):608-612.
9. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117-1127.
10. Malaspina D, Goetz RR, Friedman JH, et al. Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees. Am J Psychiatry. 2001;158(3):440-446.
11. Kofman O. The role of prenatal stress in the etiology of developmental behavioural disorders. Neurosci Biobehav Rev. 2002;26(4):457-470.
12. Malaspina D. Paternal factors and schizophrenia risk: de novo mutations and imprinting. Schizophr Bull. 2001;27(3):379-393.
13. Harkavy-Friedman J, Kimhy D, Goetz R, Malaspina D. Course of illness in schizophrenia: is there a relationship with premorbid social adjustment? Schizophr Bull. 2005;31:201.
14. Goetz D, Goetz R, Yale S, et al. Comparing early and chronic psychosis clinical characteristics. Schizophr Res. 2004;70:120.
15. Gunduz-Bruce H, McMeniman M, Robinson DG, et al. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry. 2005;162(10):1966-1969.
16. Ehrenreich H, Siren AL. Neuroprotection - what does it mean? - what means do we have? Eur Arch Psychiatry Clin Neurosci. 2001;251:149-151.
17. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999;46:729-739.
18. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361:281-288.
19. Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A. 2001;98(20):11650-11655.
20. Kasai K, Shenton ME, Salisbury DF, et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry. 2003;160:156-164.
21. Cahn W, Pol HE, Lems EB, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry. 2002;59:1002-1010.
22. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52(12):998-1007.
23. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:463-493.
24. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci. 2002;22(7):2718-2729.
25. Hashimoto T, Bergen SE, Nguyen QL, et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci. 2005;25:372-383.
26. Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry. 2004;161:882-888.
27. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry. 2000;48(7):641-650.
28. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry. 2004;161(1):109-115.
29. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry. 1998;55(3):215-224.
30. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57(1):65-73.
31. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160(8):1396-1404.
32. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
33. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62(4):361-370.
34. Mitchell IJ, Cooper AC, Griffiths MR, Cooper AJ. Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience. 2002;109:89-99.
35. Lezoualc'h F, Rupprecht R, Holsboer F, Behl C. Bcl-2 prevents hippocampal cell death induced by the neuroleptic drug haloperidol. Brain Res. 1996;738:176-179.
36. Wei Z, Bai O, Richardson JS, Mousseau DD, Li XM. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res. 2003;73:364-368.
37. Xu H, Qing H, Lu W, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett. 2002;321:65-68.
38. Ukai W, Ozawa H, Tateno M, Hashimoto E, Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm. 2004;111:667-681.
39. Huttenlocher PR, Dabholkar AS. Reginal differences in synaptogenesis in human cerebral cortex. J Comp Neurol. 1997;387:167-178.
40. Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men. Arch Gen Psychiatry. 2001;58:461-465.
41. Lees KR, Zivin JA, Ashwood T, et al. Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
42. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis. Nature. 2002;417:74-78.
43. Buchanan RW, Summerfelt A, Tek C, Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res. 2003;59:29-33.